Sir, Faropenem is a novel -lactam antimicrobial agent sharing structural similarities with both the penicillins and cephalosporins. It exhibits a broad spectrum of activity that includes Gram-negative, Gram-positive and some anaerobic bacteria.
Sir, Faropenem is a novel -lactam antimicrobial agent sharing structural similarities with both the penicillins and cephalosporins. It exhibits a broad spectrum of activity that includes Gram-negative, Gram-positive and some anaerobic bacteria. 1, 2 The primary mode of action of faropenem is consistent with that of other -lactam antibiotics, namely binding to penicillin-binding proteins. Faropenem has been shown to demonstrate high stability to a number of -lactamases, including TEM-1, SHV-1 to -5, TEM-3 to -9 and the -lactamase produced by Staphylococcus aureus NCTC 11561. 3, 4 The purpose of this study was to determine the activity of faropenem compared with cefaclor, cefpodoxime, cefixime, erythromycin, telithromycin, clarithromycin, azithromycin, levofloxacin and co-amoxiclav against the respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Bacterial strains were obtained from routine specimens collected from hospitals and clinics in South Africa. 5 Antibiotics were purchased from Sigma Chemical Co., St Louis, MO, USA, with the exception of faropenem, which was supplied by Bayer AG (Leverkusen, Germany). -Lactamase testing was carried out using the nitrocefin method (Oxoid, Basingstoke, UK), as described previously. 6 The bro gene from M. catarrhalis isolates was characterized by restriction endonuclease analysis, as described previously. Faropenem has been reported to be more active against a small number of -lactamase-producing strains of H. influenzae; 3 however, the data in this study show that faropenem activity was not influenced by -lactamase production (MIC 50 and MIC 90 , 0.5 and 1 mg/L, respectively for both -lactamase-positive and -negative isolates). Coamoxiclav and the oral cephems were also active against H. influenzae. -Lactamase production appeared to have an effect on cefaclor activity, which decreased five-to sixfold against -lactamase-producing isolates. The macrolides were not as effective against H. influenzae (MIC 90 s, 1-8 mg/L).
Against the M. catarrhalis isolates, all the agents exhibited good activity. Faropenem exhibited good activity against both -lactamase-negative and -positive isolates (MIC 90 s, Ͻ0.12 and 0.25 mg/L, respectively). The activity of the oral cephems was better against -lactamase-negative isolates (MIC 90 s Ͻ 0.12 mg/L) than against -lactamasepositive isolates (MIC 90 s 0.25-1 mg/L). Previous studies have demonstrated that strains harbouring BRO-1 -lactamases confer higher levels of resistance to the penicillins than strains harbouring BRO-2 -lactamases; however, there was no clinically meaningful increase in the MICs of the agents used in this study for BRO-1-producing isolates.
The data presented here indicate that faropenem displays useful in vitro activity against three respiratory pathogens and may be particularly useful in the treatment of pneumococcal infections caused by strains with decreased susceptibility to penicillin. 
